RECRUITING

Active Surveillance for Cancer of the Prostate (ASCaP)

Talk to us

Conditions

Prostate CancerLow riskGleason 6Active surveillance

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Active Surveillance (A.S.) of prostate cancer (CaP) is the systematic monitoring of men with low-risk, localized lesions, with curative treatment of those whose tumors show substantial progression. A.S. is different from Watchful Waiting (W.W.), which is the palliative treatment of men with progressive prostate cancer.

Official Title

The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.

Quick Facts

Study Start:2009-07-04
Study Completion:2028-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT00949819

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:30 Years to 85 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Histologically confirmed adenocarcinoma of the prostate.
  2. 2. Clinically localized prostate cancer: T1-2, NX or N0, MX or M0.
  3. 3. No previous treatment for prostate cancer (including hormonal therapy, radiation therapy, surgery, or chemotherapy).
  4. 4. Patient has elected Active Surveillance as preferred management plan for prostate cancer.
  5. 5. Patient consent has been obtained according to local Institutional Review Board .
  6. 6. Patient is accessible and compliant for follow-up.
  1. 1. Unwillingness or inability to undergo serial prostate biopsy.
  2. 2. Overall life expectancy less than 2 years
  3. 3. Advanced prostate cancer

Contacts and Locations

Study Contact

Malu Macairan
CONTACT
(310) 794-3566
mmacairan@mednet.ucla.edu
Leonard S Marks, M.D.
CONTACT
(310) 794-3070
lmarks@mednet.ucla.edu

Principal Investigator

Leonard S Marks, M.D.
PRINCIPAL_INVESTIGATOR
University of California, Los Angeles

Study Locations (Sites)

University of California Los Angeles
Los Angeles, California, 90095
United States

Collaborators and Investigators

Sponsor: Jonsson Comprehensive Cancer Center

  • Leonard S Marks, M.D., PRINCIPAL_INVESTIGATOR, University of California, Los Angeles

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2009-07-04
Study Completion Date2028-12

Study Record Updates

Study Start Date2009-07-04
Study Completion Date2028-12

Terms related to this study

Keywords Provided by Researchers

  • Prostate Cancer
  • Low risk
  • Gleason 6
  • Active surveillance

Additional Relevant MeSH Terms

  • Prostate Cancer